Atai Life Sciences FY Conference Summary Company Overview - **Company**: Atai Life Sciences (NasdaqGM: ATAI) - **Event**: Fireside Chat at the 46th Annual TD Cowen Healthcare Conference - **Date**: March 04, 2026 - **Speakers**: Srini Rao, CEO and co-founder of Atai Key Points on Lead Compound BPL-003 - **Compound**: BPL-003, an intranasal 5-MeO-DMT candidate for treatment-resistant depression (TRD) [3][4] - **Phase 3 Trials**: Two pivotal Phase 3 trials designed following positive FDA feedback from Phase 2 [8][11] - **Trial 1**: 350 patients, comparing 8 mg and 4 mg doses against placebo, with a primary endpoint at 12 weeks and an open-label extension [11][12] - **Trial 2**: Features a two-dose induction with only the 8 mg dose administered 2 weeks apart [97][98] FDA Interaction and Trial Design - **FDA Feedback**: The FDA was comfortable with the 4-week primary endpoint based on Phase 2 results [25][29] - **Placebo Control**: Both trials will use traditional placebo rather than sub-perceptual doses, aligning with recent trends in psychedelic research [30][35] - **Dosing Strategy**: The 4 mg dose is considered perceptual but putatively sub-therapeutic, while the 8 mg dose is effective [78][79] Efficacy and Safety Data - **Phase 2b Results**: Showed a 6.2 point delta between the 8 mg and 0.3 mg doses at the 4-week primary endpoint [156][157] - **Adverse Events**: Anxiety was noted as an adverse event, particularly in the 12 mg dose group, with a rate of 14% compared to 4% in placebo [175][177] - **Patient Monitoring**: Enhanced monitoring protocols for blood pressure and neurological status are being implemented for Phase 3 trials [213][215] EMP-01 for Social Anxiety Disorder - **Compound**: EMP-01, an R-enantiomer of MDMA, targeting social anxiety disorder [223][224] - **Market Size**: Approximately 15-18 million people meet criteria for social anxiety, with 6 million in the treatment-resistant group [240][241] - **Phase 1 Findings**: Showed robust psychedelic effects and entactogenic activities, prompting further exploration in a larger sample [229][233] - **Study Design**: 70 patients, with a primary endpoint measured by the Liebowitz Social Anxiety Scale (LSAS) [245][246] - **Results**: An 11.85 point delta on the LSAS was observed, comparable to SSRIs but with faster onset [245][246] Future Directions - **Next Steps**: Additional analyses and subjective elements from the EMP-01 study will be reported in the coming months to inform future trials [281][284] - **Focus on Safety**: Emphasis on generating a robust safety database due to the chronic nature of the conditions being treated [147][150] Conclusion - Atai Life Sciences is advancing its psychedelic compounds BPL-003 and EMP-01 through rigorous clinical trials, with a focus on safety, efficacy, and addressing significant unmet needs in mental health treatment. The company is positioned to leverage its findings to potentially reshape treatment paradigms in TRD and social anxiety disorder.